{"entity":{"id":"chengdu-new-radiomedicine-technology","kind":"company","name":"Chengdu New Radiomedicine Technology","aka":["Chengdu New Radiomedicine Technology Co., Ltd.","NRT Medtech","成都纽瑞特医疗科技股份有限公司"],"tldr":"Chengdu New Radiomedicine Technology is a Chinese company that makes medical radioisotopes and radioactive cancer medicines. It is testing a FAP-targeted scan agent and treatment in advanced solid tumours, and a radioactive treatment given with chemotherapy in pancreatic cancer.","summary":"Chengdu New Radiomedicine Technology Co., Ltd. (成都纽瑞特医疗科技股份有限公司, NRT Medtech) was founded in 2016 in Shuangliu, Chengdu, according to the company, and works across the radiopharmaceutical chain: medical isotope production (including yttrium-90, lutetium-177 and actinium-225, and a germanium-68/gallium-68 generator), radioactive microsphere drugs built on its own carbon microsphere carrier, and radioligand therapy. Its marketed products include yttrium-90 carbon microsphere injection. The NRT6020 programme targets fibroblast activation protein (FAP) and pairs gallium-68 for PET imaging with lutetium-177 and yttrium-90 for therapy; China's CDE cleared 90Y-NRT6020 for clinical study in October 2026. The company has subsidiaries in Australia and the United States and began IPO tutoring in 2025. Its first registered cancer trial, NCT06278454, a phase 1 dose-escalation and expansion study of NRT6008 injection with gemcitabine-nab-paclitaxel or FOLFIRINOX chemotherapy in unresectable locally advanced or node-positive advanced pancreatic cancer, was posted on ClinicalTrials.gov in February 2024. NCT06911489, a phase 1 study of 68Ga-NRT6020 and 177Lu-NRT6020 in FAP-positive advanced solid tumours, was posted in April 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"http://www.nrtmedtech.com/"},{"label":"Company news: 90Y-NRT6020 cleared for clinical study, October 2026 (Chinese)","url":"http://www.nrtmedtech.com/xinwendongtai/184.html"},{"label":"ClinicalTrials.gov: phase 1 trial of NRT6008 with chemotherapy in pancreatic cancer (NCT06278454)","url":"https://clinicaltrials.gov/study/NCT06278454"},{"label":"ClinicalTrials.gov: phase 1 trial of 68Ga- and 177Lu-NRT6020 in FAP-positive solid tumours (NCT06911489)","url":"https://clinicaltrials.gov/study/NCT06911489"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":["radiopharma"],"technologies":["radioligand-therapy","fapi-pet"],"targets":["fap"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The composition of NRT6008 is not stated in the registry record or on the pages read; it is not linked to the carbon microsphere product here.","Financing rounds and amounts are not stated on the company website.","Company website (Chinese) read on 29 October 2026."],"hq":"Chengdu","country":"CN","companyType":"radiopharma","website":"http://www.nrtmedtech.com/","founded":2016,"stage":"growth","investors":[],"funding":[]},"route":"/companies/chengdu-new-radiomedicine-technology/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/"}]}}